LXEO
Lexeo Therapeutics, Inc. Common Stock NASDAQ Listed Nov 3, 2023$4.93
-1.00%
vs $4.98
Mkt Cap $387.1M
52w Low $3.60
18.0% of range
52w High $10.99
50d MA $5.43
200d MA $7.15
P/E (TTM)
-2.6x
EV/EBITDA
—
P/B
1.5x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-3.7x
RSI (14)
45.80
ATR (14)
$0.36
Beta
2.00
50d MA
$5.43
200d MA
$7.15
Avg Volume
839.7K
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
345 PARK AVENUE SOUTH · NEW YORK, NY 10010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | TNS | -0.29 | -0.25 | +13.8% | 6.12 | -0.2% | -6.9% | +1.1% | -4.5% | -7.5% | -7.5% | — |
| Mar 30, 2026 | TNS | -0.32 | -0.27 | +15.6% | 5.27 | +11.2% | +8.9% | -1.2% | +0.9% | +0.9% | +9.4% | — |
| Nov 5, 2025 | TNS | -0.48 | -0.33 | +31.2% | 8.20 | +0.4% | +2.7% | -2.7% | +4.0% | +7.0% | +1.0% | — |
| Aug 14, 2025 | TNS | -0.64 | -0.60 | +6.2% | 4.79 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% | — |
| May 12, 2025 | TNS | -0.80 | -0.99 | -23.8% | 2.63 | +0.4% | +7.6% | -4.9% | +0.4% | +20.0% | +1.5% | — |
| Mar 24, 2025 | TNS | -0.87 | -0.78 | +10.3% | 4.09 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% | — |
| Nov 13, 2024 | TNS | -0.65 | -0.89 | -36.9% | 7.64 | +0.8% | +1.8% | -14.5% | -9.8% | +0.3% | +1.7% | — |
| Aug 12, 2024 | TNS | -0.69 | -0.64 | +7.2% | 11.98 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% | — |
| May 9, 2024 | TNS | -0.76 | -0.77 | -1.3% | 14.50 | -0.1% | -9.4% | +3.2% | +3.0% | -0.1% | +0.4% | — |
| Mar 11, 2024 | TNS | -0.73 | -0.85 | -16.4% | 14.49 | +3.0% | +8.3% | +5.7% | -5.4% | -0.7% | +0.9% | — |
| Nov 6, 2023 | TNS | -2.60 | -12.36 | -375.4% | 10.50 | +0.0% | -0.4% | +1.7% | +2.0% | -0.6% | -2.4% | — |
| Jun 30, 2023 | TNS | — | -0.53 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.74 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13 | Chardan Capital | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | +3.9% | -2.8% | -1.5% | -1.8% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.11 | -0.1% | -8.5% | +3.9% | -2.8% | -1.5% | -1.8% |
| Dec 11 | Chardan Capital | Maintains | Buy → Buy | — | $9.73 | $9.75 | +0.2% | +0.7% | -0.3% | -0.1% | -0.3% | -6.4% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $8.35 | $8.27 | -1.0% | -1.8% | +2.7% | -2.7% | +4.0% | +7.0% |
| Oct 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.22 | $9.23 | +0.1% | +4.1% | -3.9% | -2.5% | +2.6% | +6.6% |
| Oct 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Oct 7 | Chardan Capital | Maintains | Buy → Buy | — | $6.47 | $8.25 | +27.5% | +28.9% | -3.7% | +2.1% | +0.5% | -0.5% |
| Aug 15 | Chardan Capital | Maintains | Buy → Buy | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| Aug 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.79 | $4.91 | +2.5% | -1.5% | +4.2% | -2.8% | +0.4% | -0.4% |
| May 30 | JP Morgan | Maintains | Overweight → Overweight | — | $2.87 | $2.87 | +0.0% | -5.2% | +0.0% | +3.7% | +9.9% | +5.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.70 | $2.76 | +2.2% | +20.0% | +1.5% | +7.3% | -13.3% | +0.7% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +7.6% | -4.9% | +0.4% | +20.0% | +1.5% |
| May 12 | Leerink Partners | Maintains | Outperform → Outperform | — | $2.69 | $2.79 | +3.7% | -2.2% | +7.6% | -4.9% | +0.4% | +20.0% |
| Apr 8 | Chardan Capital | Maintains | Buy → Buy | — | $1.79 | $1.93 | +7.8% | +1.7% | +29.7% | -8.1% | -8.8% | +8.1% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.79 | $1.93 | +7.8% | +1.7% | +29.7% | -8.1% | -8.8% | +8.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.44 | $4.59 | +3.4% | -10.1% | +3.0% | -0.2% | -15.4% | -9.8% |
| Mar 25 | RBC Capital | Maintains | Outperform → Outperform | — | $4.09 | $4.19 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $4.09 | $4.19 | +2.4% | +8.6% | -10.1% | +3.0% | -0.2% | -15.4% |
| Mar 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $2.71 | $2.99 | +10.3% | +50.9% | +8.6% | -10.1% | +3.0% | -0.2% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $5.07 | $5.15 | +1.6% | -3.7% | +0.4% | +14.5% | -0.5% | +5.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.64 | $7.70 | +0.8% | +1.8% | -14.5% | -9.8% | +0.3% | +1.7% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $7.69 | $8.65 | +12.5% | -0.7% | +1.8% | -14.5% | -9.8% | +0.3% |
| Nov 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.69 | $8.65 | +12.5% | -0.7% | +1.8% | -14.5% | -9.8% | +0.3% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.28 | $8.31 | +0.4% | -4.6% | +0.4% | +3.9% | -2.5% | +2.1% |
| Oct 30 | Chardan Capital | Maintains | Buy → Buy | — | $9.97 | $8.85 | -11.2% | -17.0% | -4.6% | +0.4% | +3.9% | -2.5% |
| Oct 25 | Chardan Capital | Maintains | Buy → Buy | — | $9.90 | $9.91 | +0.1% | -4.0% | +3.5% | +1.4% | -17.0% | -4.6% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $11.70 | $11.83 | +1.1% | -0.1% | +3.5% | +0.9% | -2.6% | +2.4% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.98 | $11.88 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% |
| Aug 13 | RBC Capital | Maintains | Outperform → Outperform | — | $11.98 | $11.88 | -0.8% | -2.3% | -0.1% | +3.5% | +0.9% | -2.6% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.01 | $13.31 | +2.3% | -2.8% | -10.4% | -2.0% | +0.9% | +3.1% |
| Jul 15 | Chardan Capital | Maintains | Buy → Buy | — | $17.60 | $14.09 | -19.9% | -26.1% | -2.8% | -10.4% | -2.0% | +0.9% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $14.49 | $14.92 | +3.0% | +8.3% | +5.7% | -5.4% | -0.7% | +0.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Otero Jose Manuel | Chief Operating Officer | Sell | 1,302 | $5.07 | $7K | 130,088 | +2.15% | -0.20% |
| May 18, 2026 | Townsend Richard Nolan | Chief Executive Officer | Sell | 3,342 | $5.06 | $17K | 336,764 | +2.15% | -0.20% |
8-K · 8.01
!! High
Lexeo Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Lexeo Therapeutics announced a material event requiring disclosure to investors, though specific details are referenced in an attached exhibit rather than summarized in the filing text provided.
Jun 15
8-K · 2.02
!! High
Lexeo Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Lexeo Therapeutics disclosed earnings results in an 8-K filing, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 11
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
LXEO filed a material announcement regarding its genetic medicine pipeline for cardiovascular diseases, likely signaling clinical progress or strategic developments that could significantly impact the company's valuation and clinical-stage risk profile.
Mar 30
8-K · 5.02
!!! Very High
Lexeo Therapeutics, Inc. -- 8-K 5.02: Executive Change
Lexeo Therapeutics' director Adler resigned effective February 1, 2026, representing a leadership change that investors should monitor for potential impacts on company governance and strategic direction.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 4,976,429 | $29M | New | Mar 2026 |
| 2 | Citadel Advisors Llc | 3,834,999 | $22M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,007,093 | $17M | New | Mar 2026 |
| 4 | Woodline Partners Lp | 2,750,532 | $16M | Reduced | Mar 2026 |
| 5 | Avoro Capital Advisors Llc | 1,875,000 | $11M | Reduced | Mar 2026 |
| 6 | Point72 Asset Management | 1,680,449 | $10M | Reduced | Mar 2026 |
| 7 | Millennium Management | 1,612,780 | $9M | Added | Mar 2026 |
| 8 | Adar1 Capital Management, Llc | 1,467,350 | $8M | New | Mar 2026 |
| 9 | Silverarc Capital Management, Llc | 617,608 | $6M | Reduced | Dec 2025 |
| 10 | Vanguard Portfolio Management Llc | 577,192 | $3M | New | Mar 2026 |
| 11 | Northern Trust Corp | 493,666 | $3M | Added | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 491,532 | $3M | Added | Mar 2026 |
| 13 | Morgan Stanley | 280,362 | $3M | Added | Dec 2025 |
| 14 | Qube Research & Technologies Ltd | 465,515 | $3M | Added | Mar 2026 |
| 15 | Aqr Capital Management Llc | 339,623 | $2M | Added | Mar 2026 |
| 16 | Ubs Group Ag | 321,737 | $2M | Added | Mar 2026 |
| 17 | Aberdeen Group Plc | 245,904 | $1M | New | Mar 2026 |
| 18 | Jane Street Group, Llc | 140,096 | $1M | Added | Dec 2025 |
| 19 | Bnp Paribas Financial Markets | 228,201 | $1M | Reduced | Mar 2026 |
| 20 | Privium Fund Management B.v. | 205,000 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$387.1M
Enterprise Value
$302.2M
P/E (TTM)
-2.65x
Forward P/E
—
PEG Ratio
1.34x
P/B
1.48x
P/S
558.49x
P/FCF
-3.69x
EV/EBITDA
—
Shares Out
74.1M
Financials (TTM)
Revenue
$654K
Net Income
-$100.0M
EBITDA
-$97.7M
Free Cash Flow
-$99.0M
Op Cash Flow
-$98.6M
EPS Basic
$-1.86
EPS Diluted
$-1.86
EPS Forward
$-1.32
Gross Margin
0.0%
Op Margin
-16706.0%
Net Margin
-15284.6%
Balance Sheet
Total Assets
$268.7M
Total Liab.
$22.0M
Total Equity
$246.7M
Cash
$63.0M
LT Debt
$0
Book Value/Sh
$3.33
Debt/Equity
0.03x
Current Ratio
11.21
Quick Ratio
11.21
Returns & Growth
ROE
-40.5%
ROA
-37.2%
ROIC
-42.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+39.8%
Price Returns
2W
-6.5%
1M
-9.8%
3M
-28.4%
6M
-47.9%
12M
+89.0%
Technicals
52W High
$10.99
52W Low
$3.60
50d MA
$5.43
200d MA
$7.15
RSI (14)
45.80
ATR (14)
$0.36
Beta
2.00
Avg Volume
840K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.50
High
$25.00
Low
$10.00
Median
$19.50
Data updated apr 25, 2026 8:12pm
· Source: financialmodelingprep.com